TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.
News  ›  GlobeNewswire Inc.

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Rosen Law Firm
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm is investigating potential securities claims against Alvotech (NASDAQ: ALVO) following allegations of materially misleading business information. The investigation was triggered after Alvotech announced on November 2, 2025, that the FDA issued a complete response letter for its AVT05 biologics license application, citing manufacturing deficiencies. The stock fell 34% on November 3, 2025, and an additional 4% on November 4, 2025. Investors who purchased Alvotech securities may be eligible for compensation through a class action lawsuit.

Insights
TMO   positive

Positioned in an expanding market with increasing demand for diagnostic technologies

ALVO   negative

The company faces a significant stock price decline (34% on November 3, 2025) following FDA rejection of its AVT05 biologics license application due to manufacturing facility deficiencies. A securities class action investigation has been initiated, indicating potential investor harm and allegations of misleading disclosures.

Keywords
#securities fraud #FDA rejection #biologics license application #class action lawsuit #investor losses #manufacturing deficiencies

Tickers
ALVO ALVOW
← Prev: Consumer Tech News (Dec 22-26): Trump Ends "Woke" Policies at U.S. Universities, FCC Blocks Chinese Drone Competition & More